SunTrust Robinson Humphrey Downgrades INC Research Holdings Inc to Hold

Brokerage firm SunTrust Robinson Humphrey Downgrades its rating on INC Research Holdings Inc(INCR). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at SunTrust Robinson Humphrey was issued on Mar 20, 2017 in a research report to their Investors and Clients.

INC Research Holdings Inc (INCR) made into the market gainers list on Wednesdays trading session with the shares advancing 1.25% or 0.55 points. Due to strong positive momentum, the stock ended at $44.45, which is also near the day’s high of $44.5. The stock began the session at $44.5 and the volume stood at 8,39,610 shares. The 52-week high of the shares is $57.11 and the 52 week low is $36.7. The company has a current market capitalization of $2,400 M and it has 5,40,01,001 shares in outstanding.

INC Research Holdings Inc(INCR) last announced its earnings results on Feb 28, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $262.979M. Analysts had an estimated revenue of $269.000M. Earnings per share were $0.67. Analysts had estimated an EPS of $0.67.

Several Insider Transactions has been reported to the SEC. On Mar 6, 2017, Alistair Macdonald (Chief Executive Officer) sold 8,828 shares at $45.00 per share price.Also, On Jan 23, 2017, Gregory S Rush (Executive VP and CFO) sold 2,907 shares at $50.58 per share price.On Jan 23, 2017, Christopher L Gaenzle (CAO, GC & Sec) sold 1,186 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.

INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.

Add Comment